vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v23i6.2825vsp-3661Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONSСовременные возможности терапии гнездной алопецииModern Management Approaches for Alopecia Areatahttps://orcid.org/0000-0002-8232-8936АмбарчянЭ. Т.AmbarchyanEduard T.

Амбарчян Эдуард Тигранович - кандидат медицинских наук, заведующий отделением дерматологии 

117593, Москва, Литовский бульвар, д. 1а

 тел.: +7 (915) 400-00-02

Moscow

edo_amb@mail.ruhttps://orcid.org/0000-0002-6760-3119ИванчиковВ. В.IvanchikovVladislav V.

Москва

Moscow

https://orcid.org/0000-0003-3003-9398АлексееваА. Д.AlekseevaAnastasiya D.

Москва

Moscow

https://orcid.org/0000-0001-8311-9506ГордееваО. Б.GordeevaOlga B.

Москва

Moscow

https://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Москва

Moscow

НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБОУ ВО «РНЦХ им. акад. Б.В. Петровского»РоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryRussian FederationНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБОУ ВО «РНЦХ им. акад. Б.В. Петровского»; РНИМУ им. Н.И. Пирогова (Пироговский Университет)РоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical UniversityRussian Federation202406012025236516522Copyright © Амбарчян Э.Т., Иванчиков В.В., Алексеева А.Д., Гордеева О.Б., Намазова-Баранова Л.С., 20242024Амбарчян Э.Т., Иванчиков В.В., Алексеева А.Д., Гордеева О.Б., Намазова-Баранова Л.С.Ambarchyan E.T., Ivanchikov V.V., Alekseeva A.D., Gordeeva O.B., Namazova-Baranova L.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3661

Гнездная алопеция — хроническое генетически детерминированное воспалительное аутоиммунное заболевание, протекающее с поражением волосяных фолликулов, приводящим к временному или стойкому нерубцовому выпадению волос. Для лечения зарегистрированы ингибиторы янус-киназ, позволяющие персонализировать терапию и повысить ее эффективность за счет купирования симптомов и положительного влияния на качество жизни пациентов. Эта группа препаратов рассматривается в качестве основы терапии тяжелых форм гнездной алопеции. Обсуждается проблема развития рецидивов после отмены ингибиторов янус-киназ, а также безопасность длительной поддерживающей терапии препаратами этого класса.

Alopecia areata is a chronic genetically determined inflammatory autoimmune disease damaging hair follicles and leading to temporary or persistent nonscarring hair loss. Janus kinase inhibitors have been registered for its management, it allows to personalize the therapy and increase its efficacy by relieving symptoms and positively affecting patients’ quality of life. This group of drugs is considered as the basic one for the treatment of alopecia areata severe forms. The issue of disease relapses after Janus kinase inhibitors cessation and safety of long-term therapy with such drugs are covered.

гнездная алопецияингибиторы янус-киназJAKтофацитиниббарицитинибаброцитинибритлецитинибJAK/STATalopecia areataJanus kinase inhibitorsJAKtofacitinibbaricitinibabrocitinibritlecitinibJAK/STATОтсутствует.Not specified.ReferencesPasseron T, King B, Seneschal J, et al. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Front Immunol. 2023;14:1243556. doi: https://doi.org/10.3389/fimmu.2023.1243556Passeron T, King B, Seneschal J, et al. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Front Immunol. 2023;14:1243556. doi: https://doi.org/10.3389/fimmu.2023.1243556Bertolini M, McElwee K, Gilhar A, et al. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020;29(8):703–725. doi: https://doi.org/10.1111/exd.14155Bertolini M, McElwee K, Gilhar A, et al. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020;29(8):703–725. doi: https://doi.org/10.1111/exd.14155Амбарчян Э.Т., Иванчиков В.В., Аракелян А.Л. и др. Клинический случай анти-TNF-α индуцированного псориаза и псориатической алопеции у подростка с язвенным колитом // Вопросы современной педиатрии. — 2023. — Т. 22. — № 5. — С. 470–476. — doi: https://doi.org/10.15690/vsp.v22i5.2635Ambarchyan ET, Ivanchikov VV, Arakelyan AL, et al. TNF-α Inhibitor-Induced Psoriasis and Psoriatic Alopecia in Adolescent with Ulcerative Colitis: Clinical Case. Voprosy sovremennoi pediatrii — Current Pediatrics. 2023;22(5):470–476. (In Russ). doi: https://doi.org/10.15690/vsp.v22i5.2635Rudnicka L, Trzeciak M, Alpsoy E, et al. Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel. Front Med (Lausanne). 2024;11:1353354. doi: https://doi.org/10.3389/fmed.2024.1353354Rudnicka L, Trzeciak M, Alpsoy E, et al. Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel. Front Med (Lausanne). 2024;11:1353354. doi: https://doi.org/10.3389/fmed.2024.1353354Karia SB, De Sousa A, Shah N, et al. Psychiatric morbidity and quality of life in skin diseases: a comparison of alopecia areata and psoriasis. Indust Psychiatr J. 2015;24(2):125. doi: https://doi.org/10.4103/0972-6748.181724Karia SB, De Sousa A, Shah N, et al. Psychiatric morbidity and quality of life in skin diseases: a comparison of alopecia areata and psoriasis. Indust Psychiatr J. 2015;24(2):125. doi: https://doi.org/10.4103/0972-6748.181724Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol. 2014;134(4):1141–1142. doi: https://doi.org/10.1038/jid.2013.464Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol. 2014;134(4):1141–1142. doi: https://doi.org/10.1038/jid.2013.464Tan E, Tay YK, Goh CL, Chin Giam Y. The pattern and profile of alopecia areata in Singapore — a study of 219 Asians. Int J Dermatol. 2002;41(11):748–753. doi: https://doi.org/10.1046/j.1365-4362.2002.01357.xTan E, Tay YK, Goh CL, Chin Giam Y. The pattern and profile of alopecia areata in Singapore — a study of 219 Asians. Int J Dermatol. 2002;41(11):748–753. doi: https://doi.org/10.1046/j.1365-4362.2002.01357.xShellow WV, Edwards JE, Koo JY. Profile of alopecia areata: a questionnaire analysis of patient and family. Int J Dermatol. 1992;31(3):186–189. doi: https://doi.org/10.1111/j.1365-4362.1992.tb03932.xShellow WV, Edwards JE, Koo JY. Profile of alopecia areata: a questionnaire analysis of patient and family. Int J Dermatol. 1992;31(3):186–189. doi: https://doi.org/10.1111/j.1365-4362.1992.tb03932.xLee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675–682. doi: https://doi.org/10.1016/j.jaad.2019.08.032Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675–682. doi: https://doi.org/10.1016/j.jaad.2019.08.032Afford R, Leung AKC, Lam JM. Pediatric Alopecia Areata. Curr Pediatr Rev. 2021;17(1):45–54. doi: https://doi.org/10.2174/1573396316666200430084825Afford R, Leung AKC, Lam JM. Pediatric Alopecia Areata. Curr Pediatr Rev. 2021;17(1):45–54. doi: https://doi.org/10.2174/1573396316666200430084825Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clin Rev Allergy Immunol. 2021;61(3):403–423. doi: https://doi.org/10.1007/s12016-021-08883-0Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clin Rev Allergy Immunol. 2021;61(3):403–423. doi: https://doi.org/10.1007/s12016-021-08883-0Hordinsky MK. Overview of alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S13–S15. doi: https://doi.org/10.1038/jidsymp.2013.4Hordinsky MK. Overview of alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S13–S15. doi: https://doi.org/10.1038/jidsymp.2013.4Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review. Int J Dermatol. 2018;57(7):776–783. doi: https://doi.org/10.1111/ijd.13866Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review. Int J Dermatol. 2018;57(7):776–783. doi: https://doi.org/10.1111/ijd.13866McDonald KA, Shelley AJ, Colantonio S, Beecker J. Hair pull test: evidence-based update and revision of guidelines. J Am Acad Dermatol. 2017;76(3):472–477. doi: https://doi.org/10.1016/j.jaad.2016.10.002McDonald KA, Shelley AJ, Colantonio S, Beecker J. Hair pull test: evidence-based update and revision of guidelines. J Am Acad Dermatol. 2017;76(3):472–477. doi: https://doi.org/10.1016/j.jaad.2016.10.002Gómez-Quispe H, Muñoz Moreno-Arrones O, Hermosa-Gelbard Á, et al. Trichoscopy in Alopecia Areata. Tricoscopia en la alopecia areata. Actas Dermosifiliogr. 2023;114(1):25–32. doi: https://doi.org/10.1016/j.ad.2022.08.018Gómez-Quispe H, Muñoz Moreno-Arrones O, Hermosa-Gelbard Á, et al. Trichoscopy in Alopecia Areata. Tricoscopia en la alopecia areata. Actas Dermosifiliogr. 2023;114(1):25–32. doi: https://doi.org/10.1016/j.ad.2022.08.018Rossi A, Muscianese M, Piraccini BM, et al. Italian Guidelines in diagnosis and treatment of alopecia areata. G Ital Dermatol Venereol. 2019;154(6):609–623. doi: https://doi.org/10.23736/S0392-0488.19.06458-7Rossi A, Muscianese M, Piraccini BM, et al. Italian Guidelines in diagnosis and treatment of alopecia areata. G Ital Dermatol Venereol. 2019;154(6):609–623. doi: https://doi.org/10.23736/S0392-0488.19.06458-7Sibbald C. Alopecia Areata: An Updated Review for 2023. J Cutan Med Surg. 2023;27(3):241–259. doi: https://doi.org/10.1177/12034754231168839Sibbald C. Alopecia Areata: An Updated Review for 2023. J Cutan Med Surg. 2023;27(3):241–259. doi: https://doi.org/10.1177/12034754231168839Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113–117. doi: https://doi.org/10.1038/nature09114Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113–117. doi: https://doi.org/10.1038/nature09114Hayran Y, Gunindi Korkut M, Öktem A, et al. Evaluation of HLA class I and HLA class II allele profile and its relationship with clinical features in patients with alopecia areata: a case-control study. J Dermatolog Treat. 2022;33(4):2175–2181. doi: https://doi.org/10.1080/09546634.2021.1937478Hayran Y, Gunindi Korkut M, Öktem A, et al. Evaluation of HLA class I and HLA class II allele profile and its relationship with clinical features in patients with alopecia areata: a case-control study. J Dermatolog Treat. 2022;33(4):2175–2181. doi: https://doi.org/10.1080/09546634.2021.1937478Moravvej H, Tabatabaei-Panah PS, Abgoon R, et al. Genetic variant association of PTPN22, CTLA4, IL2RA, as well as HLA frequencies in susceptibility to alopecia areata. Immunol Invest. 2018;47(7):666–679. doi: https://doi.org/10.1080/08820139.2018.1480032Moravvej H, Tabatabaei-Panah PS, Abgoon R, et al. Genetic variant association of PTPN22, CTLA4, IL2RA, as well as HLA frequencies in susceptibility to alopecia areata. Immunol Invest. 2018;47(7):666–679. doi: https://doi.org/10.1080/08820139.2018.1480032Paus R, Nickoloff BJ, Ito T. A ‘hairy’ privilege. Trends Immunol. 2005;26(1):32–40. doi: https://doi.org/10.1016/j.it.2004.09.014Paus R, Nickoloff BJ, Ito T. A ‘hairy’ privilege. Trends Immunol. 2005;26(1):32–40. doi: https://doi.org/10.1016/j.it.2004.09.014Ohyama M. What is behind the ‘swarm of bees’ in alopecia areata. Br J Dermatol. 2018;179(5):1023–1024. doi: https://doi.org/10.1111/bjd.17142Ohyama M. What is behind the ‘swarm of bees’ in alopecia areata. Br J Dermatol. 2018;179(5):1023–1024. doi: https://doi.org/10.1111/bjd.17142Gilhar A, Laufer-Britva R, Keren A, Paus R. Frontiers in alopecia areata pathobiology research. J Allergy Clin Immunol. 2019;144(6):1478–1489. doi: https://doi.org/10.1016/j.jaci.2019.08.035Gilhar A, Laufer-Britva R, Keren A, Paus R. Frontiers in alopecia areata pathobiology research. J Allergy Clin Immunol. 2019;144(6):1478–1489. doi: https://doi.org/10.1016/j.jaci.2019.08.035Suchonwanit P, Kositkuljorn C, Pomsoong C. Alopecia areata: an autoimmune disease of multiple players. Immunotargets Ther. 2021;10:299–312. doi: https://doi.org/10.2147/ITT.S266409Suchonwanit P, Kositkuljorn C, Pomsoong C. Alopecia areata: an autoimmune disease of multiple players. Immunotargets Ther. 2021;10:299–312. doi: https://doi.org/10.2147/ITT.S266409Ito T. Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clin Dev Immunol. 2013;2013: 348546. doi: https://doi.org/10.1155/2013/348546Ito T. Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clin Dev Immunol. 2013;2013: 348546. doi: https://doi.org/10.1155/2013/348546Pratt CH, King LE Jr, Messenger AG, et al. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. doi: https://doi.org/10.1038/nrdp.2017.11Pratt CH, King LE Jr, Messenger AG, et al. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. doi: https://doi.org/10.1038/nrdp.2017.11Wang EHC, Yu M, Breitkopf T, et al. Identification of autoantigen epitopes in alopecia areata. J Invest Dermatol. 2016;136(8): 1617–1626. doi: https://doi.org/10.1016/j.jid.2016.04.004Wang EHC, Yu M, Breitkopf T, et al. Identification of autoantigen epitopes in alopecia areata. J Invest Dermatol. 2016;136(8): 1617–1626. doi: https://doi.org/10.1016/j.jid.2016.04.004Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049. doi: https://doi.org/10.1038/nm.3645Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049. doi: https://doi.org/10.1038/nm.3645Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342. doi: https://doi.org/10.3389/fimmu.2019.02342Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342. doi: https://doi.org/10.3389/fimmu.2019.02342Sardana K. Tyrosine kinases and JAK inhibitors. In: Systemic Drugs in Dermatology. Sardana K, ed. 2nd edn. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2022. pp. 494–499.Sardana K. Tyrosine kinases and JAK inhibitors. In: Systemic Drugs in Dermatology. Sardana K, ed. 2nd edn. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2022. pp. 494–499.Sardana K, Bathula S, Khurana A. Which is the Ideal JAK Inhibitor for Alopecia Areata — Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib — Revisiting the Immunomechanisms of the JAK Pathway. Indian Dermatol Online J. 2023;14(4):465–474. doi: https://doi.org/10.4103/idoj.idoj_452_22Sardana K, Bathula S, Khurana A. Which is the Ideal JAK Inhibitor for Alopecia Areata — Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib — Revisiting the Immunomechanisms of the JAK Pathway. Indian Dermatol Online J. 2023;14(4):465–474. doi: https://doi.org/10.4103/idoj.idoj_452_22James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. doi: https://doi.org/10.1038/nature03546James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. doi: https://doi.org/10.1038/nature03546Furumoto Y, Gadina M. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs. 2013; 27(5):431–438. doi: https://doi.org/10.1007/s40259-013-0040-7Furumoto Y, Gadina M. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs. 2013; 27(5):431–438. doi: https://doi.org/10.1007/s40259-013-0040-7Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–2990. doi: https://doi.org/10.1038/jid.2014.260Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–2990. doi: https://doi.org/10.1038/jid.2014.260Anuset D, Perceau G, Bernard P, Reguiai Z. Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata. Dermatology. 2016;232(2):242-8. doi: https://doi.org/10.1159/000441250Anuset D, Perceau G, Bernard P, Reguiai Z. Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata. Dermatology. 2016;232(2):242-8. doi: https://doi.org/10.1159/000441250Chong JH, Taïeb A, Morice-Picard F, et al. High-dose pulsed corticosteroid therapy combined with methotrexate for severe alopecia areata of childhood. J Eur Acad Dermatol Venereol. 2017;31(11):e476–e477. doi: https://doi.org/10.1111/jdv.14291Chong JH, Taïeb A, Morice-Picard F, et al. High-dose pulsed corticosteroid therapy combined with methotrexate for severe alopecia areata of childhood. J Eur Acad Dermatol Venereol. 2017;31(11):e476–e477. doi: https://doi.org/10.1111/jdv.14291Droitcourt C, Milpied B, Ezzedine K, et al. Interest of high-dose pulse corticosteroid therapy combined with methotrexate for severe alopecia areata: a retrospective case series. Dermatology. 2012;224(4):369–373. doi: https://doi.org/10.1159/000339341Droitcourt C, Milpied B, Ezzedine K, et al. Interest of high-dose pulse corticosteroid therapy combined with methotrexate for severe alopecia areata: a retrospective case series. Dermatology. 2012;224(4):369–373. doi: https://doi.org/10.1159/000339341Mascia P, Milpied B, Darrigade AS, et al. Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of alopecia areata? J Eur Acad Dermatol Venereol. 2019;33(12):e494–e495. doi: https://doi.org/10.1111/jdv.15834Mascia P, Milpied B, Darrigade AS, et al. Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of alopecia areata? J Eur Acad Dermatol Venereol. 2019;33(12):e494–e495. doi: https://doi.org/10.1111/jdv.15834Smith A, Trüeb RM, Theiler M, et al. High Relapse Rates Despite Early Intervention with Intravenous Methylprednisolone Pulse Therapy for Severe Childhood Alopecia Areata. Pediatr Dermatol. 2015;32(4):481–487. doi: https://doi.org/10.1111/pde.12578Smith A, Trüeb RM, Theiler M, et al. High Relapse Rates Despite Early Intervention with Intravenous Methylprednisolone Pulse Therapy for Severe Childhood Alopecia Areata. Pediatr Dermatol. 2015;32(4):481–487. doi: https://doi.org/10.1111/pde.12578Kiesch N, Stene JJ, Goens J, et al. Pulse steroid therapy for children‘s severe alopecia areata? Dermatology. 1997;194(4): 395–397. doi: https://doi.org/10.1159/000246159Kiesch N, Stene JJ, Goens J, et al. Pulse steroid therapy for children‘s severe alopecia areata? Dermatology. 1997;194(4): 395–397. doi: https://doi.org/10.1159/000246159Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. doi: https://doi.org/10.1016/j.jaad.2016.12.005Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. doi: https://doi.org/10.1016/j.jaad.2016.12.005Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776. doi: https://doi.org/10.1172/jci.insight.89776Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776. doi: https://doi.org/10.1172/jci.insight.89776Honap S, Cookson H, Sharma E, et al. Tofacitinib for the treatment of ulcerative colitis, alopecia universalis, and atopic dermatitis: One drug, three diseases. Inflammation Bowel Dis. 2021;27(2):e13–e14. doi: https://doi.org/10.1093/ibd/izaa243Honap S, Cookson H, Sharma E, et al. Tofacitinib for the treatment of ulcerative colitis, alopecia universalis, and atopic dermatitis: One drug, three diseases. Inflammation Bowel Dis. 2021;27(2):e13–e14. doi: https://doi.org/10.1093/ibd/izaa243Behrangi E, Barough MS, Khoramdad M, et al. Efficacy and safety of tofacitinib for treatment of alopecia areata in children: A systematic review and meta-analysis. J Cosmet Dermatol. 2022;21(12): 6644–6652. doi: https://doi.org/10.1111/jocd.15425Behrangi E, Barough MS, Khoramdad M, et al. Efficacy and safety of tofacitinib for treatment of alopecia areata in children: A systematic review and meta-analysis. J Cosmet Dermatol. 2022;21(12): 6644–6652. doi: https://doi.org/10.1111/jocd.15425Liu LY, King BA. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents. J Investig Dermatol Symp Proc. 2018;19(1):S18–S20. doi: https://doi.org/10.1016/j.jisp.2017.10.003Liu LY, King BA. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents. J Investig Dermatol Symp Proc. 2018;19(1):S18–S20. doi: https://doi.org/10.1016/j.jisp.2017.10.003Scheinberg M, de Lucena Couto Océa RA, Cruz BA, Ferreira SB. Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series. Rheumatol Ther. 2017;4(2):503–508. doi: https://doi.org/10.1007/s40744-017-0069-zScheinberg M, de Lucena Couto Océa RA, Cruz BA, Ferreira SB. Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series. Rheumatol Ther. 2017;4(2):503–508. doi: https://doi.org/10.1007/s40744-017-0069-zMurashkin NN, Ambarchian ET, Epishev RV. The National Paediatric Alopecia Areata Registry in Russia: An overview. J Am Acad Dermatol. 2022;87(3 Suppl):AB119. doi: https://doi.org/10.1016/j.jaad.2022.06.509Murashkin NN, Ambarchian ET, Epishev RV. The National Paediatric Alopecia Areata Registry in Russia: An overview. J Am Acad Dermatol. 2022;87(3 Suppl):AB119. doi: https://doi.org/10.1016/j.jaad.2022.06.509Dillon KL. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata. Clin Cosmet Investig Dermatol. 2021;14:691–714. doi: https://doi.org/10.2147/CCID.S309215Dillon KL. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata. Clin Cosmet Investig Dermatol. 2021;14:691–714. doi: https://doi.org/10.2147/CCID.S309215Bayart CB, DeNiro KL, Brichta L, et al. Topical janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167–170. doi: https://doi.org/10.1016/j.jaad.2017.03.024Bayart CB, DeNiro KL, Brichta L, et al. Topical janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167–170. doi: https://doi.org/10.1016/j.jaad.2017.03.024Kwon O, Senna MM, Sinclair R, et al. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443–451. doi: https://doi.org/10.1007/s40257-023-00764-wKwon O, Senna MM, Sinclair R, et al. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443–451. doi: https://doi.org/10.1007/s40257-023-00764-wSechi A, Song J, Dell’Antonia M, et al. Adverse events in patients treated with Jak-inhibitors for alopecia areata: A systematic review. J Eur Acad Dermatol Venereol. 2023. doi: https://doi.org/10.1111/jdv.19090Sechi A, Song J, Dell’Antonia M, et al. Adverse events in patients treated with Jak-inhibitors for alopecia areata: A systematic review. J Eur Acad Dermatol Venereol. 2023. doi: https://doi.org/10.1111/jdv.19090Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23–32. doi: https://doi.org/10.1093/bjd/ljad096Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23–32. doi: https://doi.org/10.1093/bjd/ljad096Ramírez-Marín HA, Tosti A. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata. Drug Des Devel Ther. 2022;16:363–374. doi: https://doi.org/10.2147/DDDT.S334727Ramírez-Marín HA, Tosti A. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata. Drug Des Devel Ther. 2022;16:363–374. doi: https://doi.org/10.2147/DDDT.S334727Hordinsky M, Hebert AA, Gooderham M, et al. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023;40(6):1003–1009. doi: https://doi.org/10.1111/pde.15378Hordinsky M, Hebert AA, Gooderham M, et al. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023;40(6):1003–1009. doi: https://doi.org/10.1111/pde.15378Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update. Pharmacol Res. 2024;200: 107059. doi: https://doi.org/10.1016/j.phrs.2024.107059Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update. Pharmacol Res. 2024;200: 107059. doi: https://doi.org/10.1016/j.phrs.2024.107059Bennett M, Moussa A, Sinclair R. Successful treatment of chronic severe alopecia areata with abrocitinib. Australas J Dermatol. 2022;63(2):274–276. doi: https://doi.org/10.1111/ajd.13836Bennett M, Moussa A, Sinclair R. Successful treatment of chronic severe alopecia areata with abrocitinib. Australas J Dermatol. 2022;63(2):274–276. doi: https://doi.org/10.1111/ajd.13836Zhang J, Zuo YG. Successful treatment of alopecia universalis with abrocitinib: a case report. J Dermatolog Treat. 2023;34(1):2242706. doi: https://doi.org/10.1080/09546634.2023.2242706Zhang J, Zuo YG. Successful treatment of alopecia universalis with abrocitinib: a case report. J Dermatolog Treat. 2023;34(1):2242706. doi: https://doi.org/10.1080/09546634.2023.2242706Zhao J, Liu L. A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib. JAAD Case Rep. 2022;22:99–100. doi: https://doi.org/10.1016/j.jdcr.2022.02.027Zhao J, Liu L. A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib. JAAD Case Rep. 2022;22:99–100. doi: https://doi.org/10.1016/j.jdcr.2022.02.027de Lusignan S, Alexander H, Broderick C, et al. Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study. J Allergy Clin Immunol. 2022;150(3):709–713. doi: https://doi.org/10.1016/j.jaci.2022.03.030de Lusignan S, Alexander H, Broderick C, et al. Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study. J Allergy Clin Immunol. 2022;150(3):709–713. doi: https://doi.org/10.1016/j.jaci.2022.03.030Guo H, Cheng Y, Shapiro J, McElwee K. The role of lymphocytes in the development and treatment of alopecia areata. Expert Rev Clin Immunol. 2015;11(12):1335–1351. doi: https://doi.org/10.1586/1744666X.2015.1085306Guo H, Cheng Y, Shapiro J, McElwee K. The role of lymphocytes in the development and treatment of alopecia areata. Expert Rev Clin Immunol. 2015;11(12):1335–1351. doi: https://doi.org/10.1586/1744666X.2015.1085306Jabbari A, Sansaricq F, Cerise J, et al. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. J Invest Dermatol. 2018;138(7): 1539–1545. doi: https://doi.org/10.1016/j.jid.2018.01.032Jabbari A, Sansaricq F, Cerise J, et al. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. J Invest Dermatol. 2018;138(7): 1539–1545. doi: https://doi.org/10.1016/j.jid.2018.01.032Pan Y, Kupper TS. Metabolic Reprogramming and Longevity of Tissue-Resident Memory T Cells. Front Immunol. 2018;9:1347. doi: https://doi.org/10.3389/fimmu.2018.01347Pan Y, Kupper TS. Metabolic Reprogramming and Longevity of Tissue-Resident Memory T Cells. Front Immunol. 2018;9:1347. doi: https://doi.org/10.3389/fimmu.2018.01347Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi: https://doi.org/10.1038/nri3862Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi: https://doi.org/10.1038/nri3862Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. doi: https://doi.org/10.1038/s41392-021-00791-1Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. doi: https://doi.org/10.1038/s41392-021-00791-1Wang EHC, Sallee BN, Tejeda CI, Christiano AM. JAK Inhibitors for Treatment of Alopecia Areata. J Invest Dermatol. 2018;138(9): 1911–1916. doi: https://doi.org/10.1016/j.jid.2018.05.027Wang EHC, Sallee BN, Tejeda CI, Christiano AM. JAK Inhibitors for Treatment of Alopecia Areata. J Invest Dermatol. 2018;138(9): 1911–1916. doi: https://doi.org/10.1016/j.jid.2018.05.027Sardana K, Mathachan SR, Gupta P. Pertinent role of maintenance dose of oral tofacitinib in a child with alopecia totalis with a 2.5-year follow-up on low dose. J Cosmet Dermatol. 2022;21(9):4091–4094. doi: https://doi.org/10.1111/jocd.14726Sardana K, Mathachan SR, Gupta P. Pertinent role of maintenance dose of oral tofacitinib in a child with alopecia totalis with a 2.5-year follow-up on low dose. J Cosmet Dermatol. 2022;21(9):4091–4094. doi: https://doi.org/10.1111/jocd.14726

The authors declare that there are no conflicts of interest present.